The Histone Demethylase KDM4C is a Putative Oncogene in Pancreatic Cancer
Ernesto Flores1 , MennatAllah Shaheen2, Sarah Dhebat2, Bidyut Ghosh2 , Anirban Maitra2
1Connecticut
2Sheikh

College , New London, CT

Ahmed Pancreatic Cancer Research Center, UT MD Anderson Cancer Center, Houston, TX

Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a
deadly disease that is predicted to be .the second
leading cause of cancer death in USA in 2030.The
overall 5-year survival rate for pancreatic cancer in
USA is only 11%. Figure 1 shows the multistep
progression of pancreatic cancer from normal duct to
infiltrating cancer. This progression occurs through a
series of histologically defined precursors called
Pancreatic Intraepithelial Neoplasia (PanIN), which
are precursors to pancreatic cancer (PDAC).

Methods
In our laboratory we use in-vitro and in-vivo model systems to study
KDM4C in PDAC. The in-vitro models are (i) human and mouse tissues for
assessment of KDM4C expression, and (ii) human and mouse pancreatic
cancer cell lines with CRISPR/Cas9 edited knockout of endogenous
KDM4C. For in-vivo analyses, we have athymic mice that are injected with
PDAC cells bearing knockout of KDM4C versus control lines, as well as
novel genetically engineered mouse models of PDAC with deregulated
KDM4C expression.
Only the in vitro studies are described here, which were conducted by E. F.
We used non-neoplastic and pancreatic cancer tissues from GEM models
for immunohistochemistry to determine KDM4C expression (Figure 3). We
then used control and CRISPR edited KDM4C KO MT4 cell lines to
investigate anchorage independent growth (Figure 5). Finally, Western blot
was performed to determine candidate effectors in the MAP kinase
pathway which was previously identified on profiling studies as a target of
KDM4C deregulation (Figure 4)

Results

Figure 1. Progression model for pancreatic cancer4
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In recent years epigenetic regulation including
DNA methylation and histone modifications have
been implicated in many cancers, apart from
somatic mutations. Abnormal expression of
different histone demethylases (KDMs) have been
observed in many human diseases including
cancers making them a potential therapeutic
target. Amongst them, the Kdm4 family (Kdm4A-D)
are comprised of Histone H3 lysine 9 (H3K9)
demethylase enzymes that bind to their target
gene promoters and remove trimethyl and
dimethyl group from H3K9.
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Kdm4C is overexpressed in pancreatic cancer and
may play a role in epigenetic regulation of target
genes involved in cellular proliferation and other
signaling pathways.
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Figure 5. Colony formation assay
showing absence of Kdm4C reduces
anchorage independent growth in the
Kdm4C KO cell line (2a3) compared
to the control (MT4)

Conclusion
Kdm4C is overexpressed pancreatic cancer
tissues. The downregulation of Kdm4C leads to
reduction of anchorage independent growth in the
mouse pancreatic cancer cell line MT4. The down
regulation of MAP kinase signaling pathway by
Western blot suggests that Kdm4c may be involved
in direct or indirect regulation of a key effector of
the Ras signaling pathway. All these data might be
helpful in future studies to investigate the role of
Kdm4C in regulating H3K9 methylation and
expression of oncogenic transcripts involved in
pancreatic cancer.
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Figure 2. The structure and domains of KDM4C
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Figure 3. Immuno histochemistry of KDM4C in non-neoplastic and pancreatic cancer
tissues. Upper panel shows Hematoxylin and Eosin staining of normal mouse pancreas
and GEMM model of mouse pancreatic cancer (KPL) that express oncogenic Kras along
with deletion of p53 and LKB1, an oncogene known to be mutated in pancreatic cancer.

Among the Kdm4s, Kdm4C is often amplified and
overexpressed in various cancer including
lymphoma, breast cancer, prostate cancer and lung
carcinoma. Figure 2 depicts the structure of
Kdm4C and its different protein domain. The role of
Kdm4C has not been studied in pancreatic cancer
and therefore we determined the expression of
Kdm4C in pancreas and investigated its role in
signaling pathway involved in pancreatic cancer.

Results (cont.)
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Figure 4. Western blot of control mT4 and Kdm4C KO cell lines. Upper panel shows
complete absence of Kdm4C protein following CRISPR mediated gene editing in KO lines.
Lower panels shows the down regulation of MAP kinase pathway proteins, phosphoERK1/2 and phospho-CREB as compared to control MT4 while total ERK1/2 and CREB
remains same.
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